Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05150405
Other study ID # QLF31907-101
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date October 19, 2021
Est. completion date June 1, 2024

Study information

Verified date January 2024
Source Qilu Pharmaceutical Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to evaluate the safety and tolerability of QLF31907 injection, to identify the maximum tolerated dose (MTD) and dose-limiting toxicity(DLT), and determine the recommended phase Ib dose(RPIbD) and recommended phase II dose (RP2D)in patients with advanced malignant tumors.


Recruitment information / eligibility

Status Recruiting
Enrollment 54
Est. completion date June 1, 2024
Est. primary completion date March 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Subjects voluntarily participated and signed a written informed consent form 2. Age = 18 years, male or female 3. ECOG performance status of 0 or 1 4. Expected life-expectancy of more than 3 months 5. Solid tumors: Patients with histologically diagnosed head and neck squamous cell carcinoma (HNSCC), esophageal cancer (EC), renal cancer (RCC), melanoma, cervical cancer (CC), non-oncogene driver NSCLC and other solid tumors (requiring MSI-H/ dMMR signature gene) that are locally advanced, recurrent or metastatic that have failed or are intolerant to standard therapy. Hematologic tumors: patients with histologically diagnosed mediastinal large B-cell lymphoma (PMBCL), diffuse large B-cell lymphoma (DLBCL), mesenchymal large cell lymphoma (ALCL), peripheral T-cell lymphoma (PTCL), NKT-cell lymphoma, and high-grade B-cell lymphoma (R/R HGBL) that are intolerant or relapsed/refractory to standard therapy. 6. Patients with solid tumors have at least 1 measurable lesion according to RECIST v1.1. Patients with lymphoma have at least 1 measurable lesion or hypermetabolic lesion with 18F-FDG (18F-fluorodeoxyglucose) uptake according to Lugano2014 evaluation criteria. 7. Adequate organ function prior to first use of the trail drug (no blood components, cell growth factors, leukocyte-raising drugs, platelet-raising drugs, etc., or hepatoprotective therapy is allowed within 14 days prior to obtaining laboratory tests) 1. Absolute neutrophil count = 1.5 x 109/L 2. Platelet count = 80 × 109/L (= 90 × 109/L in patients with hepatocellular carcinoma) 3. Hemoglobin = 90g/L 4. Serum creatinine = 1.5 × upper limit of normal (ULN); for patients with creatinine level > 1.5 × ULN, according to Cockcroft-Gault formula for creatinine clearance (CLcr) = 60 mL / min 5. Total bilirubin = 1.5 × ULN 6. AST and ALT = 2.5 × ULN (for Gilbert's syndrome, hepatocellular carcinoma or the presence of liver metastases, = 5 × ULN) 7. Coagulation function: prothrombin time = 1.5 × ULN, activated partial thromboplastin time = 1.5 × ULN, international normalized ratio = 1.5 × ULN 8. Cardiac left ventricular ejection fraction (LVEF) > 50% 8. Subjects (both female and male) agree to use effective contraception from the time they sign the informed consent form until 180 days after the last use of the trial drug. 9. Recovery from all the other reversible AEs from prior antineoplastic therapy prior to the first administration of the trail drug (i.e. = grade 1, according to CTCAE v5.0), excluding alopecia (any grade) and = grade 2 peripheral sensory neuropathy or lymphocytopenia. Subjects who develop other abnormalities without clinically significant or investigator-judged risk-free toxicity will be enrolled only after discussion and approval by the sponsor and investigator. Exclusion Criteria: 1. Previous treatment with 4-1BB agonist or 4-1BB recombinant fusion protein 2. Received antitumor therapy with chemotherapy, biologic therapy, endocrine therapy, immunotherapy, or monoclonal antibodies within 4 weeks prior to the first use of the trail drug, with special circumstances as follows. 1. Including those who have received oral fluorouracil analogues, small-molecule targeted drugs and herbal or Chinese patent medicine with antitumor indications within 2 weeks prior to the first use of the trail drug 2. Including those who have received mitomycin or nitrosoureas within 6 weeks prior to the first use of the trail drug 3. Including those who have received cell-based therapy or antitumor vaccine within 8 weeks prior to the first use of the trail drug 4. In subjects with a high tumor burden, treatment to reduce tumor burden for the purpose of preventing tumor lysis syndrome during the course of the trial is excluded 3. Subjects with central nervous system (CNS) metastases or clinical manifestations of CNS involvement, soft meningeal metastases, or spinal cord compression due to metastases prior to signing informed consent. Except for symptomatic CNS metastases that have been treated and stable for =4 weeks prior to the first administration of the investigational drug and who have been off systemic hormone (at any dose) therapy for >2 weeks. 4. Subjects with uncontrolled exudate or leaky fluid (thoracic, pericardial, or abdominal) or one of thoracic fluid >500 ml, pericardial fluid >100 ml, or abdominal fluid =1000 ml 5. History of autoimmune disease (including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, autoimmune hepatitis, interstitial pneumonia, uveitis, enterocolitis, hepatitis, pituitary gland inflammation, vasculitis, nephritis, hyperthyroidism, hypothyroidism [except for subjects who can be controlled by hormone replacement therapy only]; except for subjects with skin diseases that do not require systemic treatment such as vitiligo, psoriasis and alopecia areata; except for type I diabetes or asthma that has completely resolved in childhood and does not require any intervention in adulthood, such as asthma patients who require medical intervention with bronchodilators are not included) 6. Have had other active malignancies within 3 years prior to study entry (from the time of signing informed consent form). Cured basal or squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the cervix, intraductal carcinoma in situ of the breast and papillary thyroid cancer were excluded 7. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), active hepatitis (hepatitis B: defined as positive hepatitis B virus surface antigen [HBsAg] and e antigen [HBeAg] test results, or HBV-DNA = 20 IU/ml, or HBV-DNA = 1000 copies/ml, or persistent liver function abnormal, or tissue biopsy with hepatitis pathology, or cirrhosis; hepatitis C: defined as positive hepatitis C antibody [HCV-Ab] and HCV-RNA above the lower limit of detection of the analytical method), combined hepatitis B and C co-infection; syphilis spirochete infection; Mycobacterium tuberculosis infection 8. History of hepatitis (non-alcoholic steatohepatitis, alcoholic or autoimmune hepatitis) and cirrhosis 9. Subjects with the following cardiovascular events including but not limited to: myocardial infarction, severe/unstable angina, NYHA class 2 or higher cardiac insufficiency and clinically significant supraventricular or ventricular arrhythmias, prolonged QT interval and need for clinical intervention within 6 months prior to study entry (from the time of signing informed consent form); congenital heart disease such as clinically significant heart valve stenosis, insufficiency of closure and cardiomyopathy 10. Systemic antibiotic use for = 7 days within 4 weeks prior to first dose, or unexplained fever > 38.5°C during screening/prior to first dose (fever due to oncologic causes may be enrolled, as determined by the investigator) 11. Subjects with a known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation/history of bone marrow transplantation treatment, autologous stem cell transplantation within 180 days 12. Participation in any other drug clinical study within 4 weeks prior to the first dose and use of other study drugs (except minerals, vitamins), or no more than 2 weeks from the last study drug (half-life = 3 days) and no more than 28 days from the last study drug (half-life > 3 days) 13. Subjects with a known history of psychotropic substance abuse, alcohol or drug abuse; a clear previous history of neurological or psychiatric disorders, including epilepsy or dementia. 14. Known hypersensitivity to the study drug or any of its excipients; or a history of severe allergic reactions to other monoclonal antibodies; or are allergic. 15. Women who are pregnant or breastfeeding, except for women who are breastfeeding and may stop breastfeeding during the study; patients who are intending or planning to have children during the study. 16. History of idiopathic pulmonary fibrosis, pneumoconiosis, asbestosis (including drug-induced lung injury) 17. Active pneumonic lesions detected on CT chest scan during the screening period 18. Systemic immunosuppressive therapy with drugs including but not limited to glucocorticoids, cyclophosphamide, azathioprine, methotrexate, and anti-TNFa (tumor necrosis factor) drugs, except for localized and short-term small doses use within 2 weeks of the first administration of trail drug 19. Subjects who have undergone local radiation therapy for palliation within 7 days prior to the first dose; subjects who have received radiation therapy with more than 30% of the bone marrow irradiated or whole brain radiation therapy within 4 weeks prior to the first dose 20. Combined second tumor requiring concurrent treatment with other antineoplastic agents (except hormonal therapy for breast and prostate cancer) 21. Presence of uncontrolled or poorly controlled underlying respiratory, circulatory and endocrine diseases such as chronic obstructive pulmonary disease, hypertension, coronary artery disease, diabetes mellitus and hyperthyroidism 22. Presence of other serious physical or mental illnesses or abnormal laboratory tests that may increase the risk of participation in the study or interfere with the results of the study, and subjects who are not suitable for participation in this study in the opinion of the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
QLF31907
In this study, seven dose groups were proposed. The frequency of administration was once every two weeks, and four weeks was one therapeutic cycle. The subjects will receive six cycles of QLF31907 treatment at most.

Locations

Country Name City State
China Sichuan Cancer Hospital Chengdu Sichuan

Sponsors (1)

Lead Sponsor Collaborator
Qilu Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose-limiting toxicity(DLT) The DLT of QLF31907 will be determined. 28 days
Primary Maximum tolerated dose(MTD) The MTD of QLF31907 will be determined. up to 2 years
Secondary Frequency of adverse events of QLF31907 Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0. up to 2 years
Secondary Cmax of QLF31907 Peak Plasma Concentration (Cmax) of QLF31907 will be determined. up to 2 years
Secondary AUC of QLF31907 Area under the plasma concentration versus time curve (AUC) of QLF31907 will be determined. up to 2 years
Secondary Tmax of QLF31907 Time to Cmax (Tmax) of QLF31907 will be determined. up to 2 years
Secondary Immunogenicity of QLF31907 Frequency of anti-drug antibodies (ADA) against QLF31907 will be determined. up to 2 years
Secondary Anti-tumor activity of QLF31907 Solid tumor response will be determined by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1), and lymphoma response will be determined by criteria of lugano 2014. up to 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05580991 - Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors Phase 1
Recruiting NCT05691608 - MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 N/A
Active, not recruiting NCT02846038 - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Recruiting NCT05159388 - A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Recruiting NCT05981703 - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT06014502 - Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors Phase 1
Recruiting NCT04107311 - Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
Active, not recruiting NCT04078152 - Durvalumab Long-Term Safety and Efficacy Study Phase 4
Completed NCT02250157 - A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies Phase 1
Recruiting NCT05566574 - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT03943004 - Trial of DFP-14927 in Advanced Solid Tumors Phase 1
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Recruiting NCT05798546 - Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) Phase 1
Recruiting NCT05525858 - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT00479128 - Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Phase 1
Recruiting NCT04143789 - Evaluation of AP-002 in Patients With Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT04550663 - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2